

# Human Serum Albumin Binding with Erbium (III) Chloride

Rezaei Behbehani G, and Shalbafan M

**Abstract---**Erbium (III) Chloride-induced Conformational changes of human serum albumin, *HSA*, in phosphate buffer, 10mM at  $pH7.4$  were investigated, using isothermal titration calorimetry, ITC, UV and fluorescence emission spectroscopy. The results indicate that  $ErCl_3$ ,  $Er^{3+}$ , induces irreversible denaturation of the *HSA* structure. The UV absorption intensity of  $HSA + Er^{3+}$  shows the slight blue shift in the absorbance wavelength with increasing  $Er^{3+}$  concentration. The fluorescence intensity was increased regularly and the slight red shift was observed in the emission wavelength. The  $HSA + Er^{3+}$  complex increases the fluorescence of *HSA* and changes the microenvironment of tryptophan residue, suggesting the loss of the tertiary structure of *HSA*. The results obtained from the ITC data are in agreement with the spectroscopic methods. The strong negative cooperativity of  $Er^{3+}$  binding with *HSA* recovered from the extended solvation model, indicates that *HSA* has been denatured as a result of its interaction with  $Er^{3+}$  ions.

**Keywords---**Human Serum Albumin, Isothermal titration calorimetry, Fluorescence spectroscopy, Erbium (III) chloride, UV spectroscopy.

## I. INTRODUCTION

IT is well known that unfolding of some small proteins presents two-state behavior, while unfolding of multi domain proteins with populations of partially folded states involves a multi-stage process [1]. The protein stability and folding pathways are closely dependent on the various solvent ionic compositions [2]. The interactions between ions and residues in proteins can enhance the stability of some proteins. This actually suggests that specific binding of ions with residues in a protein has important implications for the biological functions of proteins [2]-[4]. *HSA* has one cysteine residue at position 34 (in domain I) with a free sulfhydryl group. *HSA* plays a special role in transporting metabolites and drugs throughout the vascular system. Aromatic and heterocyclic ligands were found to bind within two hydrophobic pockets in subdomains IIA and IIIA (figure 10), namely site I and site II [5]-[10]. *HSA* has high affinity metal binding site of the N-terminus. We have reported the  $Er^{3+}$  ions induced unfolding event of the most abundant protein contained in the plasma, human serum

Gholamreza Rezaei Behbehani (PhD) (Professor) is with Department of Chemistry, Faculty of Sciences, Imam Khomeini International University, Qazvin, Iran (e-mail: Grb402003@yahoo.com).

Monir Shalbafan is with Department of chemistry, Faculty of Sciences, Imam Khomeini International University, Qazvin, Iran (e-mail: M.shalbafan2012@yahoo.com).

albumin. The spectroscopic studies show that the *HSA* unfolding process is consistent with our previously reported ITC results, suggesting irreversible denaturation of *HSA* by  $Er^{3+}$  ions.

## II. MATERIAL AND METHODS

*HSA* was obtained from Sigma and  $ErCl_3$  was purchased from Merck. Protein concentrations were determined from absorbance measurements at 279 nm in 1 cm quartz cuvettes. All other materials and reagents were of analytical grade, and solutions were made in 50 mM buffer phosphate using double-distilled water. The UV spectra is recorded on Unico 4802 double beam spectrophotometer with protein concentration of  $20\mu M$ . All fluorescence spectra and intensities were recorded using a PERKIN Elmer Bio 100 spectrofluorimeter equipped with a xenon lamp source and 1.0cm quartz cells, excitation and emission wavelengths were 295 and 334 nm, respectively and excitation and emission bandwidths were both 5 nm. The  $HSA + Er^{3+}$  binding investigation was carried out by fluorimetric titration of *HSA* according to following titration procedure (temperature was maintained by a thermostat bath with circulating water throughout all the experiments): a cuvette of 1cm was filled with  $400\mu L(20\mu M)$  *HSA* solution. After recording the fluorescence intensities of *HSA*,  $50\mu L$  of  $ErCl_3$  stock solution ( $2000\mu M$ ) was added consecutively. The isothermal titration calorimetric experiments were carried out on a VP-ITC ultra-sensitive titration calorimeter (Micro Cal, LLC, Northampton, MA). The micro calorimeter consists of a reference cell and a sample cell of 1.8mL in volume, with both cells insulated by an adiabatic shield. All solutions were degassed by stirring under vacuum, before being used. The sample cell was loaded with *HSA* solution ( $40\mu M$ ) and the reference cell contained buffer solution. The solution in the cell was stirred at 307rpm by the syringe (equipped with micro propeller), filled with  $ErCl_3$  solution ( $500\mu M$ ) to ensure rapid mixing. The titration of *HSA* with  $ErCl_3$  solution involved 30 consecutive injections of the ligand solution, the first injection was  $5\mu L$  and the remaining ones were  $10\mu L$ . In all cases, each injection was done at 3-min intervals. To correct the thermal effects due to  $ErCl_3$  dilution, control experiments were done, in which, identical aliquots were injected into the buffer solution with the exception of *HSA*. The measurements were

performed at a constant temperature of  $27.0 \pm 0.02^\circ\text{C}$  and the temperature was controlled using a Poly-Science water bath.

### III. RESULTS AND DISCUSSION

Results of study have been shown in figures from I through XI. It is well known that *HSA* is a monomeric protein comprising 585 amino acids and its secondary structure is mainly  $\alpha$ -helix and 17 disulfide bridges. The initial crystal structure analyses have revealed that the principal regions of ligand binding sites of albumin are located in hydrophobic cavities in subdomains IIA and IIIA, and the tryptophan residue (Trp-214) is in subdomain IIA [10]-[15]. The UV absorption intensity of *HSA* decreased regularly with the addition of  $\text{Er}^{3+}$  ion concentration and the slight blue shift was observed in the wavelength with increasing  $\text{Er}^{3+}$  ion concentration (Figures I to IV).

UV spectrum of *HSA* shows two maximum at 279 and 205 nm. The band in 279 nm is related to  $\pi \rightarrow \pi^*$  transition of aromatic amino acids of tyrosine, phenylalanine and tryptophan and the absorption at 205 nm is related to the  $\pi \rightarrow \pi^*$  transition of amide groups of peptide bonds.

The intrinsic fluorescence of *HSA* is almost contributed to tryptophan, because phenylalanine has a very low quantum yield and the fluorescence of tyrosine is almost totally quenched [11]. The change of fluorescence intensity of *HSA* is related to the tryptophan residue when the small molecules are added to *HSA*. The fluorescence spectra of *HSA* at various concentrations of  $\text{Er}^{3+}$  ions are shown in figure 5. The fluorescence intensity of *HSA* increased regularly and the slight red shift was observed in the emission wavelength with increasing  $\text{Er}^{3+}$  ion concentration, indicating that the *HSA* +  $\text{Er}^{3+}$  complex was formed. Therefore, we concluded that the binding took place near Trp-214 and led to a conformational change with a local perturbation of the IIA binding site on *HSA* (figure X). Figures X to XII represent fluorescence emission spectra of the *HSA* +  $\text{Er}^{3+}$  system obtained in 0.05M phosphate buffer, pH 7.4, ionic strength 0.1, at 298K. The fluorescence intensities of *HSA* increased regularly and the slight red shift was observed for the emission wavelength with increasing  $\text{Er}^{3+}$  ion concentration, indicating that the microenvironment of tryptophan residue was changed. Therefore, we conclude that the binding took place near Trp-214 and led to a conformational change with a local perturbation of the IIA binding site in *HSA*. This increasing of emission shows the unfolding of the tertiary structure of human serum albumin.

The standard Gibbs free energy of denaturation,  $\Delta G_D^0$ , is determined based on two state process as follows:



The denaturation process can be monitored through the changes of the emission intensity at 334 nm. Assuming a two state mechanism, the denatured fraction of protein ( $F_D$ ) and the dissociation equilibrium constant of the process ( $K_D$ ) could be calculated using the following equations:

$$F_D = \frac{(Y_N - Y_{obs})}{(Y_N - Y_D)} \quad (2)$$

$$K_D = \frac{F_D}{1 - F_D} = \frac{(Y_N - Y_{obs})}{(Y_{obs} - Y_D)} \quad (3)$$

$Y_N$  and  $Y_D$  are the intensity emission of a fully native and denatured conformation of *HSA*, while  $Y_{obs}$  is the emission intensity in every stage of the unfolding process, respectively. Then the standard Gibbs free energy of denaturation ( $\Delta G_D^0$ ) can be obtained as follows:

$$\Delta G_D^0 = RT \ln K_D \quad (4)$$

$$\Delta G_D^0 = \Delta H_D - T\Delta S_D \quad (5)$$

Where R is the universal gas constant and T is the absolute temperature. Figures 8 and 9 show the free energy changes versus temperature at pH 7.4. We have shown previously that the heats of the *HSA* +  $\text{Er}^{3+}$  interactions,  $q$ , in the aqueous solvent system can be reproduced using the following equation [11]-[15]:

$$q = q_{\max} x'_B - \delta_A (x'_A L_A + x'_B L_B) - (\delta_B - \delta_A) (x'_A L_A + x'_B L_B) x'_B \quad (6)$$

The parameters of  $\delta_A$  and  $\delta_B$  reflect to the net effect of  $\text{Er}^{3+}$  ions on the *HSA* stability in the low and high  $\text{Er}^{3+}$  concentrations, respectively. The positive values for  $\delta_A$  and  $\delta_B$  indicate that the ligands stabilized the *HSA* structure, while the negative values of  $\delta_A$  and  $\delta_B$  show that *HSA* is destabilized as a result of its interaction with the ligand. If the ligand binds at each site independently, the binding is non-cooperative.  $p < 1$  or  $p > 1$  indicate positive or negative cooperativity of macromolecule for binding with ligand respectively;  $p = 1$  indicates that the binding is non-cooperative.  $x'_B$  can be expressed as:

$$x'_B = \frac{p x_B}{x_A + p x_B} \quad (7)$$

$x'_B$  is the fraction of bound  $\text{Er}^{3+}$  and  $x'_A = 1 - x'_B$  is the fraction of unbound  $\text{Er}^{3+}$ . We can express  $x_B$  fractions, as the  $\text{Er}^{3+}$  concentrations,  $[\text{Er}^{3+}]$ , after every injection divided by the maximum concentration of the  $\text{Er}^{3+}$  upon saturation of all *HSA*,  $[\text{Er}^{3+}]_{\max}$  as follows:

$$x_B = \frac{[\text{Er}^{3+}]}{[\text{Er}^{3+}]_{\max}} \quad (8)$$

$L_A$  and  $L_B$  are the relative contributions of unbound and bound  $\text{Er}^{3+}$  in the dilution heats of  $\text{Er}^{3+}$  in the absence of *HSA*. The heats of *HSA* +  $\text{Er}^{3+}$  interactions were fitted to equation 6 over the whole  $\text{Er}^{3+}$  compositions. During the procedure the only adjustable parameter (p) was changed until the good agreement between the experimental and calculated data were

approached. The binding parameters for  $HSA + Er^{3+}$  interactions recovered from equation 6 are listed in table I. The agreement between the calculated and experimental results (figure XI) gives considerable support to the use of equation 6. The results obtained from ITC data are in agreement with the spectroscopic methods. The strong negative cooperativity of  $Er^{3+}$  binding with  $HSA$  recovered from the extended solvation model ( $p=0.46$  in table I), indicates that  $HSA$  denatured as a result of its interaction with  $Er^{3+}$  ions. Destabilization of  $HSA$  by  $Er^{3+}$  ions indicates that  $Er^{3+}$  ions bind preferentially to the unfolded or partially denatured  $HSA$ . Such effects are characteristic of nonspecific interactions, in that  $Er^{3+}$  ions bind weakly to many residues of the protein, so that binding becomes a function of  $Er^{3+}$  ions, which is increased through the denaturation process. As it is clear in figure XI, there is a large structural change in a tiny range of  $Er^{3+}$  ion concentrations, suggesting a quick denaturation of  $HSA$ . These results strongly suggest that the nonspecific interactions are dominant. The positive and small value for  $\delta_A$  indicates preferential binding of  $Er^{3+}$  ions with the unfolded (or partially folded) states of  $HSA$ . This is opposed to the specific interactions that could be defined as preferential interactions between ligands and the native folded state of a protein. Therefore, both spectroscopic and calorimetric results points toward nonspecific interactions between  $HSA$  and  $Er^{3+}$  ions, suggesting irreversible denaturation of  $HSA$  by  $Er^{3+}$  ions. Erbium compounds have a high magnetic moment of 9.3 Bohr magnetons, thereby, bind to the cell surface of the microorganisms by ionic forces.

TABLE I

THERMODYNAMIC PARAMETERS FOR  $HSA + Er^{3+}$  INTERACTIONS IN  $Er^{3+}$  SOLUTION WITH WATER VIA EQUATION 6. STRONG NEGATIVE COOPERATIVITY SHOWS IRREVERSIBLE DENATURATION OF  $HSA$  BY  $Er^{3+}$  IONS.

Parameters	$HSA + Er^{3+}$
$p$	0.46
$\delta_A$	0.82
$\delta_B$	-0.19
$\Delta G^0 / \text{kJmol}^{-1}$	31.74
$\Delta H_D^0 / \text{kJmol}^{-1}$	142.00
$\Delta S_D^0 / \text{kJmol}^{-1} K^{-1}$	0.37

TABLE II

$T_m$  FOR  $HSA + Er^{3+}$  COMPLEX IS LESS THAN THAT OF PURE  $HSA$ , SUGGESTING NONSPECIFIC UNFOLDING OF  $HSA$  TOWARD IRREVERSIBLE DENATURATION OF  $HSA$ .

	$T_m / K$
$HSA$	344
$HSA + Er^{3+}$	335




Fig. 1 The effect of  $Er^{3+}$  ions on UV spectrum of  $HSA$  ( $\Delta$ ) at 298K. From up to down: 0.1cc of  $ErCl_3$  injected to  $HSA$  solution (lines). The UV absorption intensity of  $HSA$  decreased regularly with the variation of  $Er^{3+}$  ion concentration and the slight blue shift was observed in the absorbance wavelength with increasing  $Er^{3+}$  ion concentration.

Possibly, the positive charge of  $Er^{3+}$  ions interacts with protein negative charge and formed a complex in the aqueous buffer solution (50 mM, pH 7.4).




Fig. 2 Comparison between absorption spectrum of  $[HSA] = 20 \mu M$  mixture of  $HSA$  and  $[Er^{3+}] = 0.46 mM$ . The absorption peak of  $Er^{3+}$  ions ( $\Delta$ ), the absorption peak of  $HSA$  ( $\circ$ ) and the experimental absorptions for  $HSA + Er^{3+}$  complexes ( $\bullet$ ). The UV absorption intensities of  $HSA + Er^{3+}$  complex less than peak of  $HSA$ , suggesting destabilization of  $[HSA]$ . A slight blue shift was observed in the wavelength with increasing  $Er^{3+}$  ion concentration.




Fig. 3 Comparison between absorption spectrum for  $[HSA] = 20 \mu M$  and  $[Er^{3+}] = 1.66 mM$  mixtures. The absorption peak of  $Er^{3+}$  ions ( $\Delta$ ), the absorption peak of  $HSA$  ( $\circ$ ) and the experimental absorptions for  $HSA + Er^{3+}$  complexes ( $\bullet$ ). The UV absorption intensities of  $HSA + Er^{3+}$  complexes are less than the peak of  $HSA$  and the more blue shift was observed in higher concentration of  $Er^{3+}$  ions.




Fig. 4 UV spectrum of  $HSA$  ( $T = 298K$ ). The Effect of concentration of  $Er^{3+}$  ions on  $HSA$  denaturation.  $[HSA] = 2.0 \times 10^{-5} M$  and  $[ErCl_3] = 0, 181.18, 333.33, 461.53, 571.42, 750, 823.52, 888.88, 947.36, 1090.9, 1166.67$  and  $1200.56 \mu M$ .




Fig. 5 Fluorescence emission spectra of the  $HSA + Er^{3+}$  complexes obtained in  $0.05M$  phosphate buffer,  $pH 7.4$ , ionic strength  $0.1$ , at  $298K$ . The excitation wavelength was  $295nm$ . The concentration of  $HSA$  was fixed as:  $[HSA] = 20 \times 10^{-6} M$  and  $[ErCl_3] = A \times 10^{-4} M$  ( $A = 2.2, 5.4, 6.6, 7.6, 8.5, 9.3$  and  $1$ ) respectively (down to up). The fluorescence intensity of  $HSA$  increased regularly and slight red shift was observed in the emission wavelength ( $335nm$ ) with increasing  $ErCl_3$  concentration, indicating that a  $HSA + Er^{3+}$  complex increases the fluorescence intensity of  $HSA$  and changes the microenvironment of tryptophan residue.




Fig. 6 The effect of increasing temperature on fluorescence quenching of  $[HSA] = 20 \mu M$ . Thermal denaturation induces a modification of the environment of the albumin tryptophan. Denaturation is due to a redistribution of the water around the newly exposed hydrophobic residues of the protein. The reason for unfolding of  $HSA$  is the exposure of non-polar residues to a polar environment.




Fig. 7 Fluorescence quenching, indicating the denaturation of  $[HSA] = 20\mu M$  as a result of its interaction with  $[ErCl_3] = 1mM$ .




Fig. 8 Thermal denaturation curves of  $[HSA] = 20\mu M$  obtained from temperature scanning of fluorescence. The obtained  $T_m$  is  $344K$ , which can be determined on curves where  $\Delta G = 0$ .




Fig. 9 Thermal denaturation of  $[HSA] = 20\mu M + ErCl_3[1mM]$  obtained from thermal scanning of fluorescence. The calculated  $T_m$  is  $335K$ , indicating that  $Er^{3+}$  ions destabilize the  $HSA$  native structure.




Fig. 9 The three-domain structure of  $HSA$ . The protein's secondary structure is shown in different colors. (N- and C-termini are marked as N and C, respectively)




Fig. 9 Comparison between the experimental heats,  $q$ , for  $HSA + Er^{3+}$  interactions (o) and calculated data (lines) via equation 6. The sharp slope of  $q$  against  $Er^{3+}$  concentration during a tiny range of  $Er^{3+}$  concentration is indicative of irreversible nonspecific interaction.

#### IV. CONCLUSION

Denaturation of  $HSA$  structure is a very bad side effect of using  $Er^{3+}$  compounds as antiviral, cell labeling and Magnetic Resonance Image.

#### ACKNOWLEDGMENT

We appreciate all who helped us to exert the present study.

#### REFERENCES

- [1] Abu Teir M.M., Ghithan SJH., Darwish S., Abu-Hadid M.M. (2011): Study of Progesterone interaction with Human Serum Albumin: Spectroscopic Approach. *J. Appl. Biol. Sci.* 5 (13), 35-47.
- [2] Abu Teir M.M., Ghithan SJH., Darwish S., Abu-hadid M.M. (2012): Multi-spectroscopic investigation of the interactions between cholesterol and human serum albumin. *J. Appl. Biol. Sci.* 6(3), 45-55.
- [3] Ahmad B., Parveen S., Khan R.H. (2006): Effect of albumin conformation on the binding of ciprofloxacin to human serum albumin. *Biomacromolecules.* 7, 1350-1356. <http://dx.doi.org/10.1021/bm050996b>

- [4] Artali R., Bombieri G., Calabi L., Del Pra A. (2005): A molecular dynamics of human serum albumin binding sites. *Il Farmaco* 60, 485-495.  
<http://dx.doi.org/10.1016/j.farmac.2005.04.010>
- [5] Bian Q, Xu LC, Wang SL, Xia YK, Tan LF, Chen JF, Song L, Chang HC, Wang XR (2004). Study on the relation between occupational fenvalerate exposure and spermatozoa DNA damage of pesticide factory workers. *Occup. Environ. Med.* 61:999-1005.  
<http://dx.doi.org/10.1136/oem.2004.014597>
- [6] Cui F, Qin L, Zhang G, Liu X, Yao X, Lei B (2008). A concise approach to 1,11-didechloro-6-methyl-40-O-demethyl rebeccamycin and its binding to human serum albumin: Fluorescence spectroscopy and molecular modeling method. *Bioorg. Med. Chem.* 16:7615-7621.  
<http://dx.doi.org/10.1016/j.bmc.2008.07.017>
- [7] Cui F, Wang J, Cui Y, Yao X, Qu G, Lu Y (2007). Investigation of interaction between human serum albumin and N6-(2-hydroxyethyl) adenosine by fluorescence spectroscopy and molecular modelling. *Luminescence.* 22:546-553.  
<http://dx.doi.org/10.1002/bio.999>
- [8] L. Shang, Y.Z. Wang, J.G. Jiang, S.J. Dong, *Langmuir* 23 (2007), 2714–2721.  
<http://dx.doi.org/10.1021/la700700e>
- [9] J.A.O. Rumfeldt, P.B. Stathopoulos, A. Chakraborty, J.R. Lepock, E.M. Meiering, *J. Mol. Biol.* 355 (2006) 106–123.  
<http://dx.doi.org/10.1016/j.jmb.2005.10.042>
- [10] B.Haghighi, M.M. Papari and D. Shahidi. *J.Chin.Chem.Soc.* 55(2008)245.
- [11] J.Q. Liu, J.N. Tian, J.Y. Zhang, Z.D. Hu, X.G. Chen, *Anal. Bioanal. Chem.* 376 (2003) 864–867.  
<http://dx.doi.org/10.1007/s00216-003-2017-8>
- [12] J.N. Tian, J.Q. Liu, J.Y. Zhang, Z.D. Hu, X.G. Chen, *Chem. Pharm. Bull.* 51 (2003) 579–582.  
<http://dx.doi.org/10.1248/cpb.51.579>
- [13] C.Q. Jiang, M.X. Gao, X.Z. Meng, *Spectrochim. Acta A* 59 (2003) 1605–1610.  
[http://dx.doi.org/10.1016/S1386-1425\(02\)00362-1](http://dx.doi.org/10.1016/S1386-1425(02)00362-1)
- [14] A. Sulkowska, *J. Mol. Struct.* 614 (2002) 227–232.  
[http://dx.doi.org/10.1016/S0022-2860\(02\)00256-9](http://dx.doi.org/10.1016/S0022-2860(02)00256-9)
- [15] Pace CN. Measuring and increasing protein stability. *Trends Biotechnol* 1990, 8: 93-8.  
[http://dx.doi.org/10.1016/0167-7799\(90\)90146-O](http://dx.doi.org/10.1016/0167-7799(90)90146-O)
- [16] Pace CN, Trevino S, Prabhakaran E, Scholtz JM. Protein structure, stability and solubility in water and other solvents. *Philos Trans R Soc Lond B Biol Sci.* 2004, 359: 1225-34.  
<http://dx.doi.org/10.1098/rstb.2004.1500>
- [17] G. Rezaei Behbehani, M. mehreshtiagh, L. Barzegar, A. A. Saboury, *J. Serb. Chem. Soc.* 78 (2) 255–263 (2013).
- [18] G. Rezaei Behbehani, A. Divsalar, A. A. Saboury, A. A. Hekmat, *J. Solution Chem.* 38 (2009) 219.  
<http://dx.doi.org/10.1007/s10953-008-9360-5>
- [19] G. Rezaei Behbehani, M. Mirzaie, *J. Therm. Anal. Calorim.* 96 (2009) 631.  
<http://dx.doi.org/10.1007/s10973-008-9311-9>
- [20] G. Rezaei Behbehani, A. A. Saboury, M. Mohebbian, S. Tahmasbi Sarvestani, M. Poorheravi, *Chin. Chem. Lett.* 20 (2009) 1389  
<http://dx.doi.org/10.1016/j.ccllet.2009.05.029>
- [21] G. Rezaei Behbehani, A. A. Saboury, A. Fallah Bagheri, A. Abedini, *J. Therm. Anal. Calorim.* 93 (2008) 479  
<http://dx.doi.org/10.1007/s10973-007-8674-7>